Search

everythinglearnresearchcommunity

for

Search:↓

The combination of vitamin D analogues with potent steroids is a favorable treatment for alopecia areata with fewer side effects.

Methotrexate treatment for rheumatoid arthritis has a serious infection rate of about two per 100 patient-years.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.

High mTORC1 activity slows hair growth and causes it to lose color.

Lenalidomide effectively and safely treats skin symptoms in pediatric lupus, reducing the need for prednisone.

Ritlecitinib shows promise for hair regrowth in alopecia areata patients.

Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.

Mesenchymal stem cell therapy shows promise for treating certain inflammatory skin diseases, but more research is needed.

A(1-7) treatment reduces symptoms of lupus in mice.

Switching Janus kinase inhibitors helped some patients with severe alopecia areata regrow hair, but insurance issues can worsen the condition.

Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.

JAK inhibitors help with skin conditions but need more research on dosing and safety.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.

Cyclosporine can treat skin conditions but needs careful monitoring for side effects.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.

CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.

Two transplant patients on cyclosporine unexpectedly developed hair loss.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Oral cyclosporine A and prednisolone effectively improved alopecia universalis without side effects.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Rituximab can cause skin issues, but baricitinib may help improve them.

Aggressive immunosuppressive treatment improved a woman's severe heart condition linked to autoimmune disease.